Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.85 - $1.43 $374,238 - $629,601
-440,281 Reduced 19.57%
1,809,719 $1.66 Million
Q2 2023

Aug 14, 2023

BUY
$1.12 - $1.49 $280,000 - $372,500
250,000 Added 12.5%
2,250,000 $2.68 Million
Q1 2023

May 15, 2023

SELL
$1.19 - $2.19 $12.8 Million - $23.6 Million
-10,790,559 Reduced 84.36%
2,000,000 $3 Million
Q4 2022

Feb 14, 2023

BUY
$1.07 - $1.34 $4.3 Million - $5.38 Million
4,014,403 Added 45.74%
12,790,559 $15.5 Million
Q3 2022

Nov 14, 2022

BUY
$1.09 - $1.67 $9.57 Million - $14.7 Million
8,776,156 New
8,776,156 $9.57 Million
Q2 2020

Aug 14, 2020

SELL
$4.78 - $8.26 $2.16 Million - $3.73 Million
-451,243 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$4.0 - $21.53 $1.8 Million - $9.72 Million
451,243 New
451,243 $1.81 Million

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $222M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.